IGM Biosciences, Inc.

NasdaqGS:IGMS 株式レポート

時価総額：US$403.1m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

IGM Biosciences マネジメント

マネジメント 基準チェック /34

IGM Biosciences'の CEO はFred Schwarzerで、 Jul2010年に任命され、 の在任期間は 13.92年です。 の年間総報酬は$ 3.21Mで、 20.2%給与と79.8%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.41%を直接所有しており、その価値は$ 1.75M 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と5.8年です。

主要情報

Fred Schwarzer

最高経営責任者

US$3.2m

報酬総額

CEO給与比率20.2%
CEO在任期間13.9yrs
CEOの所有権0.4%
経営陣の平均在職期間3.2yrs
取締役会の平均在任期間5.8yrs

経営陣の近況

Recent updates

IGM Biosciences: Unlikely To Move The Needle Again In 2024

May 12

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?

Apr 28
Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Feb 12

We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

Nov 20
We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn

May 10
We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Jan 05
Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Sep 23
IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Aug 29

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Aug 08

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Jun 09
We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

IGM Biosciences: Interesting Science, Poor Trial Data

Feb 23

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?

Feb 17
Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Sep 07
Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

May 25
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

Feb 08
IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

IGM Biosciences reports quick assets and provides business updates

Jan 13

Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares

Dec 18
Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares

IGM Bio prices upsized $200M public offering

Dec 09

IGM Biosciences proposes public offering

Dec 07

IGM Biosciences (IGMS) Investor Presentation - Slideshow

Nov 20

CEO報酬分析

IGM Biosciences の収益と比較して、Fred Schwarzer の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$237m

Dec 31 2023US$3mUS$647k

-US$246m

Sep 30 2023n/an/a

-US$238m

Jun 30 2023n/an/a

-US$234m

Mar 31 2023n/an/a

-US$229m

Dec 31 2022US$5mUS$622k

-US$221m

Sep 30 2022n/an/a

-US$219m

Jun 30 2022n/an/a

-US$205m

Mar 31 2022n/an/a

-US$185m

Dec 31 2021US$10mUS$598k

-US$165m

Sep 30 2021n/an/a

-US$139m

Jun 30 2021n/an/a

-US$115m

Mar 31 2021n/an/a

-US$95m

Dec 31 2020US$5mUS$530k

-US$81m

Sep 30 2020n/an/a

-US$72m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$53m

Dec 31 2019US$757kUS$428k

-US$43m

Sep 30 2019n/an/a

-US$37m

Jun 30 2019n/an/a

-US$34m

Mar 31 2019n/an/a

-US$27m

Dec 31 2018US$519kUS$376k

-US$23m

報酬と市場: Fredの 総報酬 ($USD 3.21M ) は、 US市場 ($USD 2.46M ) の同規模の企業の平均を上回っています。

報酬と収益: Fredの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Fred Schwarzer (71 yo)

13.9yrs

在職期間

US$3,207,328

報酬

Mr. Fred M. Schwarzer, J.D., was a Founder of Charter Life Sciences, a venture capital firm specializing in life sciences investments, in 2003 and served as its Managing Partner from inception until August...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Fred Schwarzer
CEO, President & Director13.9yrsUS$3.21m0.42%
$ 1.7m
Bruce Keyt
Chief Scientific Officer11.8yrsUS$1.57m0.18%
$ 741.0k
Chris Takimoto
Chief Medical Officer2.9yrsUS$1.56m0.045%
$ 181.1k
Misbah Tahir
Chief Financial Officer5.4yrsUS$1.08m0.028%
$ 113.8k
TS Harigopal
Senior Vice President of Group Operations1.4yrsデータなしデータなし
Steven Weber
Senior VP2.3yrsデータなし0.0032%
$ 12.8k
Paul Graffagnino
Senior Vice President of Legal Affairs3.4yrsデータなしデータなし
Suzette Tauber
Chief Human Resources Officer5yrsデータなしデータなし
Angus Sinclair
Senior Vice President of Immuno-Oncology2.8yrsデータなしデータなし
Lisa Decker
Chief Business Officer3.3yrsUS$4.92m0.029%
$ 117.1k
Marvin Peterson
Executive Vice President of Process Development & Manufacturing3.2yrsデータなしデータなし
Mary Harler
Head of Research & Autoimmunity2.7yrsデータなし0.14%
$ 582.1k

3.2yrs

平均在職期間

59.5yo

平均年齢

経験豊富な経営陣: IGMSの経営陣は 経験豊富 であると考えられます ( 3.2年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Fred Schwarzer
CEO, President & Director21.3yrsUS$3.21m0.42%
$ 1.7m
Felix Baker
Independent Director3.4yrsUS$168.55k0%
$ 0
M. Behrens
Independent Director5.4yrsUS$178.30k0.68%
$ 2.7m
Mark Davis
Member of Scientific Advisory Boardno dataデータなしデータなし
Rafi Ahmed
Member of Scientific Advisory Boardno dataデータなしデータなし
Michael Lee
Independent Director4.9yrsUS$166.09k0.0099%
$ 40.0k
Jakob Topsoe
Independent Director5.8yrsUS$166.09k0.14%
$ 579.5k
Julie Hambleton
Independent Director5.8yrsUS$204.09k0.0034%
$ 13.7k
Christina Topsoe
Independent Director5.8yrsUS$175.84k0.090%
$ 364.8k
William Strohl
Independent Director5.8yrsUS$236.59k0%
$ 0
Elizabeth Thompson
Independent Directorless than a yearUS$167.54k0.0025%
$ 9.9k
Gordon J. Freeman
Member of Scientific Advisory Boardno dataデータなしデータなし

5.8yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: IGMSの 取締役会 は 経験豊富 であると考えられます ( 5.8年の平均在任期間)。